Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer

Background:  Human glandular kallikrein (hK2) has been shown to add important information regarding the early detection and staging of prostate cancer. Preliminary analysis pointed out that hK2 may discriminate between pT2 and pT3 tumors, and that hK2 may predict Gleason grade 4/5 cancer volume, better than prostate‐specific antigen (PSA) or percent free PSA (% fPSA). We investigated the role of hK2 serum values for predicting pathological stage, grade and Gleason score.

[1]  P. Nelson,et al.  New nomenclature for the human tissue kallikrein gene family. , 2000, Clinical chemistry.

[2]  A. Haese*,et al.  Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. , 2000, The Journal of urology.

[3]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[4]  W. Catalona,et al.  Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. , 2002, The Journal of urology.

[5]  M. Brawer,et al.  Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. , 1997, British journal of urology.

[6]  P. Wong,et al.  Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. , 1999, Clinical biochemistry.

[7]  J. Richie,et al.  Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. , 1999, The Journal of urology.

[8]  H. Lilja,et al.  Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. , 2000, Clinical chemistry.

[9]  J. Pannek,et al.  The use of percent free prostate specific antigen for staging clinically localized prostate cancer. , 1998, The Journal of urology.

[10]  Z. Hall.  Cancer , 1906, The Hospital.

[11]  B. G. Blijenberg,et al.  The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. , 1997, The Journal of urology.

[12]  G. Kristiansen,et al.  Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. , 2000, Urology.

[13]  J. Oesterling,et al.  Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. , 2000, The Journal of urology.

[14]  S. Loening,et al.  Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  J. Oesterling,et al.  Serum percent-free PSA does not predict extraprostatic spread of prostate cancer. , 1998, American journal of clinical pathology.

[16]  E. Diamandis,et al.  The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease , 2001, Critical reviews in clinical laboratory sciences.

[17]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.

[18]  D. Tindall,et al.  Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. , 1999, Clinical chemistry.

[19]  K. Harada,et al.  Preoperative prediction of final pathological features is not improved by the free‐to‐total prostate‐specific antigen ratio in Japanese men with clinically localized prostate cancer , 2005, International journal of urology : official journal of the Japanese Urological Association.

[20]  P. Humphrey,et al.  Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. , 1998, Urology.

[21]  J. Trachtenberg,et al.  Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Chan,et al.  Standardization of two immunoassays for human glandular kallikrein 2. , 2003, Clinical chemistry.

[23]  P. Abrahamsson,et al.  Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. , 2003, The Journal of urology.

[24]  B. G. Blijenberg,et al.  Comparison of two assays for human kallikrein 2. , 2003, Clinical chemistry.

[25]  J. Richie,et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. , 2000, Urology.

[26]  B. G. Blijenberg,et al.  The value of (−7, −5)pro‐prostate‐specific antigen and human kallikrein‐2 as serum markers for grading prostate cancer , 2004, BJU international.

[27]  Christoph,et al.  primary structure , 2020, Catalysis from A to Z.

[28]  V. Lorusso.  Prostate Carcinoma , 2002, Tumori.

[29]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[30]  Stig Nordling,et al.  Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue , 2005, The Prostate.

[31]  W. Catalona,et al.  The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. , 1999, Clinical chemistry.

[32]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[33]  Carter Hb,et al.  PSA velocity for the diagnosis of early prostate cancer. A new concept. , 1993 .

[34]  J. Morote,et al.  Use of Percent Free Prostate–Specific Antigen as a Predictor of the Pathological Features of Clinically Localized Prostate Cancer , 2000, European Urology.

[35]  D. Tindall,et al.  Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. , 1999, Urology.

[36]  E. Diamandis,et al.  Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. , 1999, Clinical chemistry.

[37]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[38]  M. Kattan,et al.  The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer , 2003, The Prostate.

[39]  H. Carter,et al.  PSA velocity for the diagnosis of early prostate cancer. A new concept. , 1993, The Urologic clinics of North America.

[40]  K. Jung,et al.  Factors influencing the ratio of free to total prostate‐specific antigen in serum , 1997, International journal of cancer.

[41]  L. Baert,et al.  Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. , 1996, The Journal of urology.

[42]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[43]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[44]  A. Haese*,et al.  Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml , 2001, The Prostate.

[45]  T. Piironen,et al.  Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. , 2000, Urology.

[46]  D. Tindall,et al.  Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.

[47]  G G Klee,et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.

[48]  T. Piironen,et al.  In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. , 1998, Urology.

[49]  Hartwig Huland,et al.  Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. , 2003, The Journal of urology.

[50]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.